EMA Application withdrawn: Faldaprevir Boehringer Ingelheim (faldaprevir) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA withdrew the application for faldaprevir by Boehringer Ingelheim International GmbH for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Faldaprevir (faldaprevir)

Snippet

Status: Application withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Boehringer Ingelheim International GmbH. Decision date: 27/06/2014